

The Link Between Atrial Fibrillation And Cognitive Impairment: A Systematic Review And Meta-Analysis

Short Title: "Atrial Fibrillation and Cognitive Impairment: A Meta-analysis"

Abhimanyu Agarwal MBBS¹; Mohamed A. Mostafa MBBCh¹; Muhammad Imtiaz Ahmad MD MS²;

Elsayed Z. Soliman MD, MSc, MS¹

1. Epidemiological Cardiology Research Center, Section on Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
2. Department of Internal Medicine, Section on Hospital Medicine, Medical College of Wisconsin, Wauwatosa, Wisconsin

Corresponding Author

Abhimanyu Agarwal, MBBS

Epidemiological Cardiology Research Center (EPICARE)

Wake Forest School of Medicine

Medical Center Blvd, Winston Salem, NC 27157

Email: abhsworld@gmail.com, abagarwa@wakehealth.edu

Tel: 704-201-3548; Fax: 336-716-9188

Conflict of Interest Statement:

Authors hereby declare that we have no conflicts of interest to disclose regarding the work presented in this meta-analysis "**The Link Between Atrial Fibrillation And Cognitive Impairment: A Systematic Review And Meta-Analysis**".

Funders: No funds, grants, or other support was received.

Keywords

AF, Cognitive Impairment, Dementia, Meta-analysis, Stroke.

Word Count

Abstract: 150 words.

Number of References: 66

Number of Tables: 1

Number of Figures: 3

Abstract

Atrial fibrillation (AF) affects a substantial population of individuals aged ≥ 55 years globally and has been associated with an increased risk of cognitive impairment (CImp) due to the shared risk factors such as aging, obesity, and diabetes. It is essential to comprehend their unique relationship to manage them effectively to reduce its impact on public health systems. We performed a PubMed search of English language papers published till 31 May 2023. Data was extracted and effect measures were calculated. Meta-analysis of 33 studies revealed a significant association between AF and CImp after adjusting for comorbidities, with considerable between-study heterogeneity (pooled OR: 1.62; 95% CI: 1.43, 1.81, $I^2 = 94.143$). Prospective and cross-sectional studies revealed substantial associations. CImp in AF may be mediated through silent brain infarctions, microemboli, brain atrophy, and inflammation. Future research should prioritize investigating the mechanisms and etiology of this association, as well as potential treatment options.

Keywords

AF, Cognitive Impairment, Dementia, Meta-analysis, Stroke.

List of Abbreviations

AF:	Atrial Fibrillation
CImp:	Cognitive Impairment
MMSE:	Mini Mental State Exam

MoCA: Montreal Cognitive Assessment

INTRODUCTION

Atrial fibrillation has been dubbed as the 21st-century cardiovascular disease epidemic¹⁻⁴. With approximately 33 million people worldwide aged 55 and over affected by it, it is common among the elderly. AF is presently the most widely treated arrhythmia in clinical settings^{5,6} with \$26 billion in healthcare costs related to its management and complications. Asia is predicted to have 72 million AF patients by 2050, with 2.9 million of them at risk for strokes linked to AF⁷. One in nine persons has subjective cognitive decline (SCD) and is more prevalent in people ≥ 65 years old compared to younger populations aged 45 to 64 (11.7% vs. 10.8%), respectively. Additionally, according to the Centers for Disease Control (CDC), 10.6% of women and 11.3% of men have SCD. It is crucial to remember that AF is associated with a 39% higher risk of cognitive impairment (CImp)⁸.

The shared risk factors between AF and CImp, such as aging, heart disease, obesity, diabetes, etc.^{8,9}, which can occur alone or in combination⁵, underscore the need to investigate association between these risk factors and AF to develop preventive strategies. Studies demonstrate an increased risk of CImp and dementia associated with AF¹⁰, irrespective of a history of stroke^{11,12}. Similar risk ratio estimates of 2.43¹³ and 2.70¹¹ for CImp/dementia among people with AF were found in two meta-analyses. Persistent AF, but not paroxysmal AF, was associated with worse cognitive performance, according to an analysis of the Atherosclerosis Risk in Communities (ARIC) study¹⁴. These results imply that AF duration may have an additional effect on cognitive performance in addition to a mere presence of AF¹⁵⁻¹⁸.

There is significant consumption of Public health resources due to AF and its associated complications including CImp¹⁹. Worldwide, approximately 35.6 million people were estimated to have dementia in 2010, and it is predicted that this figure would roughly double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050²⁰. A comprehensive review that only considers studies involving individuals with no history of stroke to examine the association between AF and CImp is required to draw more conclusive findings. By establishing a relationship between AF and CImp independent of stroke or other CVD risk factors, it will highlight the urgent need to develop strategies to mitigate this significant relationship.

METHODS

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)²¹ standards, this systematic review and meta-analysis were conducted.

Data Sources

PubMed database was systematically searched from inception until 31 May 2023 using the search terms “Atrial Fibrillation and Cognitive Decline”, “Atrial Fibrillation and Cognitive Impairment”, “Atrial Fibrillation and Cognitive Function”, and “Atrial Fibrillation and Dementia” were utilized to retrieve studies involving individuals with cognitive impairment. Additionally, the references of the included studies and pertinent reviews were screened to identify any additional eligible studies. In total, 2892 studies were included in the search process.

Study Selection

This systematic review included studies which met the following inclusion criteria:

1. Publication in the English language through May 2023.
2. Investigating the relationship between AF and CImp.
3. Reporting event rates or relative risks (RR)/odds ratios (OR) or hazard ratios (HR) for comparison groups.
4. Encompassing all observational study designs (cohort, cross-sectional, prospective, retrospective).

5. Studies in which cognitive assessment was done using standardized assessment scales eg Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Modified Mini-Mental State Examination (3MS), informant questionnaire on cognitive decline in the elderly (IQCODE), Delayed Word Recall Test (DWRT), Wechsler Adult Intelligence Scale-Revised's Digit Symbol Substitution Test (DSST), Word Fluency Test (WFT), etc.

Exclusion Criteria:

1. Studies with patients who had experienced stroke/ were suffering from vascular dementia/ underwent surgery/ had underlying psychological disorders/ cancer.
2. Patients taking antiarrhythmic medications.
3. Studies discussing pathophysiology of AF and dementia.
4. Did not report data about cognitive decline or only have brain imaging results/biomarkers/genetic markers.
5. Did not present original data, or were editorials, case reports, case series, systematic reviews/meta analysis.

Using the established criteria, we reviewers assessed the eligibility of studies included.

Study Identification

We screened articles by title and abstract using predefined inclusion and exclusion criteria and a standardized data form. If the article did not meet inclusion criteria based on the

abstract, the full text was not reviewed. The inclusion of full text was decided by consensus. All results were exported to Zotero, an open-source research tool for organizing and analyzing data, where duplicates were eliminated.

Data Extraction and Outcomes

A structured data collection form was employed to gather information from each study, including study design, patient characteristics, baseline variables, cognitive evaluation method, follow-up duration in years, AF ascertainment. In cases where duplicate studies were found and studies reported the same outcome measure, only the larger study was included in the analysis.

Quality Assessment

A consensus was reached to address any differences. The included studies' epidemiological and clinical data were extracted using standardized forms. The Newcastle–Ottawa Scale (NOS) was employed to evaluate the quality of the article. NOS score ≥ 6 stars were defined as high quality, and NOS score < 6 stars as low quality.

Data Analysis

We extracted study baseline characteristics, event rates and sample sizes and calculated odds ratio for the primary and secondary outcomes using JASP 0.17.2.1 and the Campbell Effect Size Calculator for all statistical calculations. Statistics were deemed significant at a p-value of 0.05 level of significance.

When both Clmp and dementia associations were separately reported, the outcome for the entire population was considered, as dementia is a subpopulation of Clmp. We utilized

meta-regression analysis and subgroup analysis (comparing cross-sectional and cohort studies) to explore potential sources of variance across studies. Age, hypertension, coronary artery disease, diabetes mellitus, and hyperlipidemia were all taken into account during the meta-regression analysis. Several sensitivity assessments were also conducted to investigate AF's association with CImp/dementia beyond stroke.

A random-effects model was used to account for variability within and across studies. The Higgins I-squared statistic (I^2) was used to determine the degree of heterogeneity. The risk of publication bias was shown using funnel plots and quantified using Egger's regression test. To display the impact magnitude in each research and the combined estimate, a forest plot was used. A subgroup analysis was carried out to look at how the study design (cohort vs. cross-sectional) affected the result.

RESULTS

This meta-analysis included 33 studies^{12,18,22-52} in total, and Figure 1 shows a thorough flow diagram of the method used to choose the studies. Table 1 shows characteristics of the sample population included. Of these investigations, two were case-control studies, four were retrospective in nature, 23 had a prospective design, and four provided cross-sectional analyses. Between 57 and 665,330 people were enrolled in the studies that were considered. Electrocardiogram (ECG) and the MMSE were the two tests that were used the most commonly to diagnose AF and Clmp, respectively. The funnel plot was examined visually, and Egger's test ($p = 0.296$) revealed that there was no publication bias.

Analysis of Individual Results

The analysis involved 33 studies^{12,18,22-52} in total, and the pooled analysis showed a significant correlation between AF and an elevated risk of outcome of interest i.e. Clmp (pooled OR: 1.62; 95% CI: 1.43, 1.81; df: 32) with significant between-study heterogeneity ($I^2 = 94.143$, $\tau^2 = 0.080$, $\tau = 0.283$, $h^2 = 17.072$) (Figure 2, 3). The cook's distance examined the influence measurements and found six outlier studies^{18,23,30,34,39,47}. The between-study heterogeneity was marginally reduced once these outliers were taken into account (27 studies; pooled OR: 1.58; 95% CI: 1.38, 1.79; df: 26; $I^2 = 93.320$).

Hypertension: A pooled analysis of 19 studies^{12,18,22,23,24,27,28,30,32,34,37-39,43,45,46,49-51} that included patients with concomitant hypertension revealed a significant correlation between AF and Clmp (OR: 1.73; 95% CI: 1.49, 1.97; df: 18). Hypertension was a covariate that had a

significant degree of between-study heterogeneity (91.42%). However, it was unable to fully account for the variation in effect size ($Q = 130.887$; $df, 17$; $p = 0.001$).

Diabetes Mellitus: A substantial correlation between AF and Clmp was found in the pooled analysis of 20 studies^{12,18,22,23,24,27,28,30,32,34,37,38,39,43,45,48-51} that included individuals with DM comorbidity (OR: 1.75; 95% CI: 1.52, 1.98; $df: 19$). Similar to hypertension, DM as a covariate exhibited substantial between-study heterogeneity (92.52%) and did not fully explain the variation in effect size ($Q = 219.471$; $df = 18$; $p < 0.001$).

Hyperlipidemia: The pooled analysis of the seven studies^{18,27,28,32,43,49,50} that included patients with hyperlipidemia as a comorbidity revealed a significant correlation between AF and Clmp (OR: 2.00; 95% CI: 1.50, 2.51; $df: 6$). When utilizing hyperlipidemia as a covariate, the between-study heterogeneity was considerable (44.645%), but it could account for all of the variations in the effect magnitude ($Q = 7.168$; $df = 5$; $p = 0.179$).

Myocardial Infarction (MI): A substantial correlation was found between AF and Clmp (OR: 1.75; 95% CI: 1.44, 2.06; $df: 7$), according to a pooled analysis of eight studies^{12,18,23,30,37,48,49,50} reporting patients with MI comorbidity. When MI was included as a covariate, there was significant between-study heterogeneity (90.334%), but it did not fully explain the observed variation in effect size ($Q = 85.425$; $df = 6$; $p < 0.001$).

Heart Failure (HF): The pooled analysis showed a significant correlation between AF and Clmp among 10 studies^{12,22,23,24,28,37,39,46,48,50} reporting patients with HF comorbidity (OR: 1.49; 95% CI: 1.24, 1.74; $df: 9$). When utilizing HF as a covariate, there was significant between-study

heterogeneity (90.765%), and it could not completely account for the observed variability in effect size ($Q = 148.580$; $df = 8$; $p < 0.001$).

Stroke: The pooled analysis of the 10 studies^{22,30,38,39,43,46,48,49,50,51} that reported patients with concomitant strokes revealed a significant correlation between AF and CImp (OR: 1.63; 95% CI: 1.39, 1.88; $df = 9$). When stroke was included as a covariate, there was considerable between-study heterogeneity (75.695%), but it was unable to fully account for the variation in effect size ($Q = 38.029$; $df = 8$; $p < 0.001$).

Smoking: The pooled analysis of the eleven studies^{12,18,23,24,30,38,40,43,46,49,50} that included patients who smoked showed a substantial correlation between AF and CImp (OR: 1.74; 95% CI: 1.52, 1.96; $df = 10$). When smoking was included as a covariate, there was considerable between-study heterogeneity (41.625%), and the smoking covariate could account for all of the variation in effect size ($Q = 11.196$; $df = 9$; $p = 0.263$).

Sensitivity Analysis using Sub-groups

Study Design: Even when the analysis was restricted to certain study designs, significant findings were still observed for the combined endpoint of CImp and/or dementia. There was a significant correlation in 23 prospective studies^{12,22,24,26,29-31,33,35,36,38,39,41,42,43,44,46-52} (OR: 1.57; 95% CI: 1.38, 1.75; $df = 22$; $I^2 = 79.278\%$). A significant correlation was also seen in cross-sectional studies, which included 4 studies^{25,27,34,45} (OR: 2.06; 95% CI: 1.16, 2.96; $df = 3$; $I^2 = 84.313\%$). Case-control studies (2 studies^{23,32}) (OR: 1.96; 95% CI: 0.53, 3.39; $df = 1$) and retrospective studies (4 studies^{18,28,37,40}) (OR: 1.52; 95% CI: 0.86, 2.18; $df = 3$; $I^2 = 98.199\%$) resulted in non-significant association.

Comprehensive Cognitive Testing

Sub-groups that used more sensitive neuropsychological tests^{12,18,22,26-29,31,33-40,42,44-46} rather than relying simply on MMSE testing, showed that AF was substantially associated with an increased risk of CImp (OR: 1.60, 95% CI: 1.31, 1.88, df: 19, $I^2 = 96.367\%$). Similarly, AF was shown to be substantially linked with CImp in subgroups that solely underwent MMSE testing^{23,24,30,41,47-52} (OR: 1.70, 95% CI: 1.52, 1.87, df: 9, $I^2 = 53.896\%$).

DISCUSSION

This systematic review and meta-analysis aimed to assess the relationship between AF and Clmp. The analysis of 33 observational studies revealed a significant association between AF and an elevated risk of the combined endpoint of Clmp and/or dementia. Additional analyses were conducted, focusing on studies that employed sensitive neuropsychological testing, to address the heterogeneity in methodologies used to identify Clmp and these secondary analyses further supported the substantial correlation between AF and Clmp. The observed variability can be attributed to variations in sample size, study design and population differences.

To address the issue of significant heterogeneity, we used a random-effects model and several subgroups, sensitivity, and meta-regression analyses. However, still significant heterogeneity existed. Importantly, our study exclusively included individuals without a history of stroke, revealing a strong association between AF and Clmp.

The study by Kokkinidis et. al. revealed that individuals with AF have 3.11 times higher odds of developing dementia, 1.60 times higher odds of Clmp, and a 2.26 times higher odds of experiencing either Clmp/dementia compared to those without AF⁵⁴. Several other studies also found similar associations between AF and Clmp^{9,11,33,47,55-58}. However, further investigation is needed to understand how AF affects cognitive performance in diverse ethnic and geographic populations. Interestingly, sex and race have been found to interact significantly with Clmp among individuals with AF⁵⁹.

In addition to its risk of thromboembolism, recent research suggests that AF increases the chance of Clmp through various pathophysiological pathways and processes. Silent brain infarctions, microemboli, microbleeds, brain atrophy, cerebral hypoperfusion, altered hemostatic function, vascular oxidative stress, and inflammation are a few reasons that contribute to this association⁸. These factors may lead to more severe Clmp in patients with chronic or permanent AF, longer duration of AF, or a higher burden of AF⁶⁰. Furthermore, AF is associated with an inflammatory state, and it is unknown whether AF-induced systemic inflammation contributes to dementia⁹. Both Clmp and AF share several common risk factors, as they primarily affect the elderly population. Silent brain infarctions, and clinically apparent ischemic strokes are likely processes behind the elevated risk of Clmp complicating AF in this age group^{60,61}. Some studies suggest that anticoagulant therapy, including direct oral anticoagulants and vitamin K antagonists, may reduce the incidence of Clmp and dementia in patients with AF. However, silent brain infarction still occurs among individuals with AF despite on anticoagulation⁶². Therefore, randomized trials⁵⁶ are still needed to provide conclusive evidence that anticoagulation reduces the risk of Clmp and dementia in AF patients. Future research should also explore the potential advantages of increasing the use of oral anticoagulation or enhancing adherence to anticoagulant treatment in specific patient subgroups^{61,63}.

AF has been associated with decreased volume in the right basal frontal lobe and right inferior cerebellum⁶⁴, taking into account the existence of hypertension and a history of heart failure. There is growing evidence that the aging process, hypertension, and AF are all connected to structural and functional changes in various parts of the central nervous system

that affect autonomic control⁶⁵. Furthermore, the link between AF and dementia persists even after accounting for common risk factors such as diabetes and hypertension⁹. According to Bano et. al.⁶⁶, diabetes is associated with a higher likelihood of neurological comorbidities such as stroke (OR: 1.39; 95% CI: 1.03, 1.87) and Clmp (OR: 1.75; 95% CI: 1.39, 2.21). Therefore, effective management of co-existent risk factors such as hypertension, diabetes, and so on and how it will impact the association of AF with Clmp should be explored in large clinical trials.

Several limitations should be considered when interpreting the findings of this study. The inclusion of case-control and retrospective studies, along with prospective studies led to greater heterogeneity and therefore limits our ability to draw any firm conclusions. This highlights the need for further research using robust study designs to elucidate the relationship between AF and Clmp. The included studies employed diverse methods and criteria to identify AF, Clmp, and dementia which likely contributed to significant heterogeneity. We addressed this by employing a random-effects model and carrying out numerous subgroup, sensitivity, and meta-regression studies. The studies had a wide confidence interval, which suggested differences in the research methodology and participant demographics may have contributed to less accurate estimates. Although the exclusion of outlier studies led to a modest decrease in heterogeneity, it did not reach statistical significance.

In conclusion, this meta-analysis provides strong evidence linking the association between AF and poor cognitive function. Despite between-study heterogeneity and the influence of multiple comorbidities, the findings demonstrate a link between AF and an increased risk of Clmp. Future studies should focus on investigating the underlying reasons and

potential therapeutic interventions to mitigate cognitive decline in AF patients. Given high morbidity and its significant impact on the quality of life, our findings have implications for patients and healthcare systems considering the burden of AF due to increasing life expectancy.

1. Contributors:

Study design, literature review, statistical analysis: AA.

Data management, drafting manuscript: AA, MAM, MIA.

Access to data: AA, MAM, MIA, EZS

Manuscript revision, intellectual revisions, mentorship: MIA, EZS

Final approval: AA, MAM, MIA, EZS

2. Funders: No funds, grants, or other support was received.

3. Prior presentations: This paper has not been presented anywhere else.

REFERENCES

1. Mehta NK, Strickling J, Mark E, et al. Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation. *Prog Cardiovasc Dis.* 2021;66:2-9. doi:10.1016/j.pcad.2021.05.002
2. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet Lond Engl.* 2015;386(9989):154-162. doi:10.1016/S0140-6736(14)61774-8
3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation.* 2014;129(8):837-847. doi:10.1161/CIRCULATIONAHA.113.005119
4. Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med.* 1997;337(19):1360-1369. doi:10.1056/NEJM199711063371906
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation.* 2014;130(23):2071-2104. doi:10.1161/CIR.0000000000000040
6. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Heart Rhythm.*

2017;14(10):e275-e444. doi:10.1016/j.hrthm.2017.05.012

7. Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol*. 2015;17 Suppl 2:ii31-39. doi:10.1093/europace/euv231
8. Koh YH, Lew LZW, Franke KB, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol*. 2022;24(8):1229-1239. doi:10.1093/europace/euac003
9. Madhavan M, Graff-Radford J, Piccini JP, et al. Cognitive dysfunction in atrial fibrillation. *Nat Rev Cardiol*. 2018;15(12):744-756. doi:10.1038/s41569-018-0075-z
10. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? *EP Eur*. 2018;20(3):408-419. doi:10.1093/europace/eux031
11. Kalantarian S, Stern TA, Mansour M, et al. Cognitive impairment associated with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 2013;158(5 Pt 1):338-346. doi:10.7326/0003-4819-158-5-201303050-00007
12. Kim D, Yang PS, Yu HT, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. *Eur Heart J*. 2019;40(28):2313-2323. doi:10.1093/eurheartj/ehz386
13. Kwok CS, Loke YK, Hale R, et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. *Neurology*. 2011;76(10):914-922.

doi:10.1212/WNL.0b013e31820f2e38

14. Chen LY, Agarwal SK, Norby FL, et al. Persistent but not Paroxysmal Atrial Fibrillation Is Independently Associated With Lower Cognitive Function: ARIC Study. *J Am Coll Cardiol.* 2016;67(11):1379-1380. doi:10.1016/j.jacc.2015.11.064
15. Alonso A, Arenas de Larriva AP. Atrial Fibrillation, Cognitive Decline And Dementia. *Eur Cardiol.* 2016;11(1):49-53. doi:10.15420/ecr.2016:13:2
16. Islam MM, Poly TN, Walther BA, et al. Association Between Atrial Fibrillation and Dementia: A Meta-Analysis. *Front Aging Neurosci.* 2019;11. doi:10.3389/fnagi.2019.00305
17. Liu DS, Chen J, Jian WM, et al. The association of atrial fibrillation and dementia incidence: a meta-analysis of prospective cohort studies. *J Geriatr Cardiol JGC.* 2019;16(3):298-306. doi:10.11909/j.issn.1671-5411.2019.03.006
18. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. *Heart Rhythm.* 2010;7(4):433-437. doi:10.1016/j.hrthm.2009.12.004
19. Dagues N, Chao TF, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol.* 2018;20(9):1399-1421. doi:10.1093/europace/euy046

20. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement J Alzheimers Assoc.* 2013;9(1):63-75.e2. doi:10.1016/j.jalz.2012.11.007
21. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Int J Surg Lond Engl.* 2021;88:105906. doi:10.1016/j.ijso.2021.105906
22. Chen LY, Norby FL, Gottesman RF, et al. Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20 Years: The ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). *J Am Heart Assoc.* 2018;7(6):e007301. doi:10.1161/JAHA.117.007301
23. Di Nisio M, Prisciandaro M, Rutjes AWS, et al. Dementia in patients with atrial fibrillation and the value of the Hachinski ischemic score. *Geriatr Gerontol Int.* 2015;15(6):770-777. doi:10.1111/ggi.12349
24. Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. *Neurology.* 2018;91(19):e1732-e1740. doi:10.1212/WNL.0000000000006456
25. Dugger BN, Malek-Ahmadi M, Monsell SE, et al. A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases. *Alzheimer Dis Assoc Disord.* 2016;30(3):223-229. doi:10.1097/WAD.000000000000138
26. Forti P. Atrial fibrillation is associated with an increased risk of cognitive impairment and

- dementia with or without a history of clinical stroke. *Evid Based Med*. 2014;19(1):e3.
doi:10.1136/eb-2013-101342
27. Horstmann S, Rizos T, Rauch G, et al. Atrial fibrillation and prestroke cognitive impairment in stroke. *J Neurol*. 2014;261(3):546-553. doi:10.1007/s00415-013-7233-3
28. Liao JN, Chao TF, Liu CJ, et al. Risk and prediction of dementia in patients with atrial fibrillation--a nationwide population-based cohort study. *Int J Cardiol*. 2015;199:25-30. doi:10.1016/j.ijcard.2015.06.170
29. Marengoni A, Qiu C, Winblad B, et al. Atrial fibrillation, stroke and dementia in the very old: a population-based study. *Neurobiol Aging*. 2011;32(7):1336-1337. doi:10.1016/j.neurobiolaging.2009.08.002
30. Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. *CMAJ Can Med Assoc J J Assoc Medicale Can*. 2012;184(6):E329-336. doi:10.1503/cmaj.111173
31. Rastas S, Verkkoniemi A, Polvikoski T, et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. *Stroke*. 2007;38(5):1454-1460. doi:10.1161/STROKEAHA.106.477299
32. Salehi R, Enamzadeh E, Goldust M. Study of cognitive disorders in stroke-free patients with a history of atrial fibrillation. *Pak J Biol Sci PJBS*. 2013;16(1):44-47. doi:10.3923/pjbs.2013.44.47
33. Singh-Manoux A, Fayosse A, Sabia S, et al. Atrial fibrillation as a risk factor for cognitive

- decline and dementia. *Eur Heart J*. 2017;38(34):2612-2618. doi:10.1093/eurheartj/ehx208
34. Kawabata-Yoshihara LA, Scazufca M, Santos I de S, et al. Atrial fibrillation and dementia: results from the Sao Paulo ageing & health study. *Arq Bras Cardiol*. 2012;99(6):1108-1114. doi:10.1590/s0066-782x2012005000106
35. Salvadori E, Barucci E, Barbato C, et al. Cognitive phenotypes and factors associated with cognitive decline in a cohort of older patients with atrial fibrillation: The Strat-AF study. *Eur J Neurol*. 2023;30(4):849-860. doi:10.1111/ene.15701
36. Sumida H, Yasunaga Y, Takasawa K, et al. Cognitive function in post-cardiac intensive care: patient characteristics and impact of multidisciplinary cardiac rehabilitation. *Heart Vessels*. 2020;35(7):946-956. doi:10.1007/s00380-020-01566-4
37. Clua-Espuny JL, Muria-Subirats E, Ballesta-Ors J, et al. Risk of Atrial Fibrillation, Ischemic Stroke and Cognitive Impairment: Study of a Population Cohort ≥ 65 Years of Age. *Vasc Health Risk Manag*. 2020;16:445-454. doi:10.2147/VHRM.S276477
38. Xiong N, Shen J, Wu B, et al. Factors influencing cognitive function in patients with atrial fibrillation: a cross-sectional clinical study. *J Int Med Res*. 2019;47(12):6041-6052. doi:10.1177/0300060519882556
39. BONNESEN MP, DIEDERICHSEN SZ, ISAKSEN JL, et al. Atrial fibrillation burden and cognitive decline in elderly patients undergoing continuous monitoring. *Am Heart J*. 2021;242:15-23. doi:10.1016/j.ahj.2021.08.006
40. Alam AB, Kulshreshtha A, Li L, et al. Associations of Atrial Fibrillation with Mild Cognitive

Impairment and Dementia: An Investigation Using SPRINT Research Materials. *J Clin Med*. 2022;11(19):5800. doi:10.3390/jcm11195800

41. Malavasi VL, Zoccali C, Brandi MC, et al. Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. *Int J Cardiol*. 2021;323:83-89. doi:10.1016/j.ijcard.2020.08.028
42. Dublin S, Anderson ML, Haneuse SJ, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. *J Am Geriatr Soc*. 2011;59(8):1369-1375. doi:10.1111/j.1532-5415.2011.03508.x
43. Graff-Radford J, Madhavan M, Vemuri P, et al. Atrial fibrillation, cognitive impairment, and neuroimaging. *Alzheimers Dement J Alzheimers Assoc*. 2016;12(4):391-398. doi:10.1016/j.jalz.2015.08.164
44. Krupenin P, Gabitova M, Bordovsky S, et al. Impact of atrial fibrillation on the rate of mild cognitive impairment in the elderly. *J Neurol Sci*. 2018;394:75-77. doi:10.1016/j.jns.2018.08.023
45. Yang H, Niu W, Zang X, Lin M, Zhao Y. The association between atrial fibrillation and cognitive function in patients with heart failure. *Eur J Cardiovasc Nurs*. 2017;16(2):104-112. doi:10.1177/1474515116641299
46. Alonso A, Knopman DS, Gottesman RF, et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *J Am Heart Assoc*. 2017;6(7):e006014.

doi:10.1161/JAHA.117.006014

47. Bellomo A, De Benedetto G, Fossati C, et al. Atrial fibrillation (AF) and cognitive impairment in the elderly: a case-control study. *Arch Gerontol Geriatr.* 2012;55(2):247-250. doi:10.1016/j.archger.2011.07.017
48. Bilato C, Corti MC, Baggio G, et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). *Am J Cardiol.* 2009;104(8):1092-1097. doi:10.1016/j.amjcard.2009.05.058
49. Coma M, González-Moneo MJ, Enjuanes C, et al. Effect of Permanent Atrial Fibrillation on Cognitive Function in Patients With Chronic Heart Failure. *Am J Cardiol.* 2016;117(2):233-239. doi:10.1016/j.amjcard.2015.10.038
50. Polidoro A, Stefanelli F, Ciacciarelli M, et al. Frailty in patients affected by atrial fibrillation. *Arch Gerontol Geriatr.* 2013;57(3):325-327. doi:10.1016/j.archger.2013.04.014
51. Pulignano G, Del Sindaco D, Tinti MD, et al. Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. *J Cardiovasc Med Hagerstown Md.* 2016;17(8):616-623. doi:10.2459/JCM.0000000000000366
52. Haring B, Leng X, Robinson J, et al. Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. *J Am Heart Assoc.* 2013;2(6):e000369. doi:10.1161/JAHA.113.000369
53. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. *Stroke.* 1997;28(2):316-321.

doi:10.1161/01.str.28.2.316

54. Kokkinidis DG, Zareifopoulos N, Theochari CA, et al. Association Between Atrial Fibrillation and Cognitive Impairment in Individuals With Prior Stroke: A Meta-Analysis and Meta-Regression Analysis. *Stroke*. 2020;51(6):1662-1666.

doi:10.1161/STROKEAHA.119.027815

55. Papanastasiou CA, Theochari CA, Zareifopoulos N, et al. Atrial Fibrillation Is Associated with Cognitive Impairment, All-Cause Dementia, Vascular Dementia, and Alzheimer's Disease: a Systematic Review and Meta-Analysis. *J Gen Intern Med*. 2021;36(10):3122-3135.

doi:10.1007/s11606-021-06954-8

56. Diener HC, Hart RG, Koudstaal PJ, et al. Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019;73(5):612-619.

doi:10.1016/j.jacc.2018.10.077

57. Alosco ML, Spitznagel MB, Sweet LH, et al. Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure. *Pacing Clin Electrophysiol PACE*. 2015;38(2):178-186. doi:10.1111/pace.12543

58. Sepehri Shamloo A, Dages N, Müssigbrodt A, et al. Atrial Fibrillation and Cognitive Impairment: New Insights and Future Directions. *Heart Lung Circ*. 2020;29(1):69-85.

doi:10.1016/j.hlc.2019.05.185

59. Bailey MJ, Soliman EZ, McClure LA, et al. Relation of Atrial Fibrillation to Cognitive Decline (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). *Am J*

Cardiol. 2021;148:60-68. doi:10.1016/j.amjcard.2021.02.036

60. Manolis TA, Manolis AA, Apostolopoulos EJ, et al. Atrial Fibrillation and Cognitive Impairment: An Associated Burden or Burden by Association? *Angiology*. 2020;71(6):498-519. doi:10.1177/0003319720910669
61. Blum S, Conen D. Mechanisms and Clinical Manifestations of Cognitive Decline in Atrial Fibrillation Patients: Potential Implications for Preventing Dementia. *Can J Cardiol*. 2023;39(2):159-171. doi:10.1016/j.cjca.2022.10.013
62. Kühne M, Krisai P, Coslovsky M, et al; Swiss-AF Investigators. Silent brain infarcts impact on cognitive function in atrial fibrillation. *Eur Heart J*. 2022 Jun 6;43(22):2127-2135. doi:10.1093/eurheartj/ehac020. PMID: 35171989; PMCID: PMC9170478.
63. Cheng W, Liu W, Li B, Li D. Relationship of Anticoagulant Therapy With Cognitive Impairment Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. *J Cardiovasc Pharmacol*. 2018;71(6):380-387. doi:10.1097/FJC.0000000000000575
64. Silva DS, Caseli BG, de Campos BM, et al. Cerebral Structure and Function in Stroke-free Patients with Atrial Fibrillation. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. 2021;30(8):105887. doi:10.1016/j.jstrokecerebrovasdis.2021.105887
65. Rim D, Henderson LA, Macefield VG. Brain and cardiovascular-related changes are associated with aging, hypertension, and atrial fibrillation. *Clin Auton Res Off J Clin Auton Res Soc*. 2022;32(6):409-422. doi:10.1007/s10286-022-00907-9
66. Bano A, Rodondi N, Beer JH, et al. Association of Diabetes With Atrial Fibrillation Phenotype

and Cardiac and Neurological Comorbidities: Insights From the Swiss-AF Study. *J Am Heart Assoc.* 2021;10(22):e021800. doi:10.1161/JAHA.121.021800

List of Tables:

Table 1: Basic Characteristics Of Study Population

List of Figures:

Figure 1: Study Selection Using Prisma Technique

Figure 2: Random Effects Meta Analysis Of Risk Of Cognitive Decline In Atrial Fibrillation Patients

Figure 3: Funnel Plot

Table 1: Basic Characteristics of Study Population

Study No	First Author	Type of Study	AF and CI	AF and Non CI	Non AF and CI	Non AF and Non CI	Total Patients	Follow up time (in months)	Mean Age AF Pt (in years)	Mean Age Non AF Pt (in years)	Neurological assessment Scale
1	Kim et al. ¹²	prospective	2065	8370	33980	218196	262611	75	71.7	70.7	KDSQ, ICD-10
2	Bunch T J et al. ¹⁸	retrospective	731	9430	804	26060	37025	60	68.1	57.8	ICD-9
3	Chen L Y et al. ²²	prospective	180	1831	977	9527	12515	240	59.3	56.4	DWRT, DSST, WFT
4	Di Nisio M et al. ²³	case control	87	16	161	45	309	NA	77.7	77.4	MMSE
5	Ding M et al. ²⁴	prospective	80	399	214	1878	2571	108	80.9	72.3	MMSE

6	Dugger B N et al. ²⁵	cross sectional	537	545	8482	7968	17532	NA	NA	NA	NA
7	Forti P et al. ²⁶	prospective	8	16	80	507	611	36	NA	NA	MMSE, CDR
8	Horstman S et al. ²⁷	cross sectional	37	125	59	549	770	NA	75.5	64.5	IQCODE
9	Liao J N et al. ²⁸	retrospective	29012	303653	27889	304776	665330	NA	70.3	70.3	ICD-9-CM
10	Marengoni A et al. ²⁹	prospective	18	50	152	465	685	72	NA	NA	MMSE, ICD-9
11	Marzona et al. ³⁰	prospective	1050	2018	7269	20595	30932	56	69.0	66.3	MMSE
12	Rastas S et al. ³¹	prospective	50	72	164	267	553	108	85.0	85.0	DSM-III R criteria

13	Salehi R et al. ³²	case control	3	90	1	95	189	12	71.1	71.3	NA
14	Singh-Ma noux A et al. ³³	prospective	50	862	274	9028	10214	320	NA	NA	Cognitive test battery
15	Kawabata-Yoshihara L A et al. ³⁴	cross sectional	4	33	62	1425	1524	42	77.7	72.1	DSM-IV
16	Salvadori E et al. ³⁵	prospective	16	45	19	48	128	17	NA	NA	MoCA
17	Sumida H et al. ³⁶	prospective	22	14	34	41	111	NA	NA	NA	FIM
18	Clua-Espu ny J L et al. ³⁷	retrospecti ve	126	1118	3791	41671	46706	NA	81.0	79.3	NIHSS, rankin score
19	Xiong N et al. ³⁸	prospective	80	70	61	89	300	NA	71.2	71.2	MMSE, MES

20	Bonnesen M P et al. ³⁹	prospective	55	284	119	736	1194	36	NA	76.7	MoCA
21	Alam A B et al. ⁴⁰	retrospective	120	854	738	6757	8469	NA	72.4	67.2	MoCA
22	Malavasi V L et al. ⁴¹	prospective	45	210	18	164	437	30	NA	NA	MMSE
23	Dublin S et al. ⁴²	prospective	103	399	469	2074	3045	82	76.5	74.2	Cognitive Abilities Screening Instrument, Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition)
24	Graff-Radford J et al. ⁴³	prospective	33	108	127	776	1044	15	80.7	77.2	NA

25	Krupenin P et al. ⁴⁴	prospective	20	28	32	18	98	NA	78.0	76.0	MoCA
26	Yang H et al. ⁴⁵	cross sectional	47	25	56	60	188	NA	68.9	64.6	MoCA
27	Alonso A et al. ⁴⁶	prospective	237	374	1476	4345	6432	NA	79.0	76.0	National Institute of Aging–Alzheimer's Association workgroups
28	Bellomo A et al. ⁴⁷	prospective	8	18	8	23	57	NA	71.4	72.1	MMSE
29	Bilato C et al. ⁴⁸	prospective	73	62	519	922	1576	48	79.0	74.0	MMSE
30	Coma M et al. ⁴⁹	prospective	80	107	215	479	881	NA	75.9	71.7	MMSE
31	Polidoro A et al. ⁵⁰	prospective	49	21	38	32	140	NA	79.3	79.1	MMSE

32	Pulignano G et al. ⁵¹	prospective	27	71	38	195	331	NA	78.0	77.0	MMSE
33	Haring B et al. ⁵²	prospective	21	234	386	5792	6433	100	NA	NA	MMSE




Figure 1: Study selection using PRISMA technique




Figure 2: Random-effects meta-analysis of risk of Cognitive Decline in patients with Atrial Fibrillation

Figure 2: Random Effects Meta Analysis Of Risk Of Cognitive Decline In Atrial Fibrillation Patients




Figure 3: Funnel Plot